• Anlotinib Hydrochloride: Interpreting Angiogenesis Assays

  2026-09-25

  Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor for studying how angiogenic signals shape endothelial behavior. This article focuses on a practical question often missed in assay guides: how to distinguish target engagement from a genuine, interpretable anti-angiogenic phenotype.

• H 89 2HCl for PKA Signaling in Osteoclasts

  2026-09-25

  Use H 89 2HCl as a downstream PKA perturbation to test whether cAMP/PKA activity contributes to dopamine-associated changes in CREB phosphorylation and osteoclast differentiation. A concentration-aware workflow, matched vehicle controls, and orthogonal readouts help distinguish pathway effects from H 89’s broader kinase inhibition.

• Sunitinib Assay Workflows: From RTK Signal to Readout

  2026-09-24

  A practical guide to using Sunitinib (SKU B1045) in cell viability, proliferation, and cytotoxicity studies. It connects RTK biology with assay design, compound handling, result interpretation, and evidence-aware product selection.

• Imatinib hydrochloride: Kinase Research Workflows

  2026-09-24

  Build reproducible CML and GIST experiments with Imatinib hydrochloride, pairing dose-response studies with target-specific phospho-signaling readouts. A recent p38α kinase–phosphatase study offers useful assay-design ideas—but does not show that imatinib has the same dual-action mechanism.

• Dovitinib Workflows for RTK-Driven Cancer Research

  2026-09-23

  Dovitinib (TKI-258) helps researchers test whether RTK signaling supports cancer-cell survival, using linked pathway and phenotype readouts rather than viability alone. This workflow also shows how to explore RTK dependence in therapy-resistant models without assuming that Dovitinib directly targets HER2 or EDI3.

• Triiodothyronine and Beige-Fat Mechanisms

  2026-09-23

  Triiodothyronine (T3) provides a precise hormonal perturbation for investigating thermogenic adipocyte biology. This article connects T3 assay design with SEMA3E–β-catenin evidence while distinguishing established findings from testable experimental hypotheses.

• Anlotinib and Selective VEGFR2 Inhibition

  2026-09-22

  The reference study established anlotinib as a highly potent, orally active VEGFR2 inhibitor whose principal preclinical effect was suppression of tumor angiogenesis rather than direct tumor-cell cytotoxicity. Its integrated kinase, endothelial, ex vivo vessel, and xenograft experiments provide a useful framework for interpreting anti-angiogenic activity in cancer research.

• Nebivolol hydrochloride in β1 Signaling Research

  2026-09-22

  Nebivolol hydrochloride provides a selective way to isolate β1-adrenergic receptor signaling in cardiovascular models while serving as a useful negative comparator in mTOR screens. This guide translates its chemistry, assay handling, and the 2025 drug-sensitized yeast findings into reproducible workflows and troubleshooting decisions.

• Nebivolol Hydrochloride: Orthogonal Assay Design

  2026-09-21

  Nebivolol hydrochloride is a selective β1-adrenoceptor antagonist for precise cardiovascular pharmacology research. This article shows how to interpret its receptor-focused activity alongside a drug-sensitized yeast screen that tests, rather than assumes, mTOR pathway cross-reactivity.

• S1P Signaling: From Vascular Biology to ICH

  2026-09-21

  Sphingosine-1-phosphate is not simply a survival lipid: its biological output depends on receptor context, cell type, and injury state. This article connects S1P biology with S1PR3-driven neuronal apoptosis after intracerebral hemorrhage and translates that mechanism into a receptor-aware experimental strategy.

• EDI3 Inhibition in HER2 Therapy-Resistant Breast Cancer

  2026-09-20

  Keller et al. identify the glycerophosphodiesterase EDI3/GPCPD1 as a choline-metabolism dependency in ER-HER2-positive breast cancer, including models resistant to HER2-targeted therapy. Their combination of patient-tissue profiling, signaling perturbation, genetic silencing, pharmacological inhibition, and in vivo testing supports EDI3 as a candidate target, while leaving its clinical selectivity and mechanism of viability loss for further study.

• Phillygenin in Diabetic Nephropathy: Mechanisms and Evidence

  2026-09-19

  The reference study identifies phillygenin as a potential renoprotective compound that limits inflammation and apoptosis in diabetic nephropathy through coordinated regulation of TLR4/MyD88/NF-κB and PI3K/AKT/GSK3β signaling. Its combination of RNA sequencing, podocyte experiments, and db/db mouse validation provides a mechanistic preclinical framework, while the absence of human and target-specific validation defines important next steps.

• ABT-263: A Senescence-Resolved Apoptosis Strategy

  2026-09-18

  ABT-263 (Navitoclax) can do more than induce apoptosis: it can help reveal how therapy-induced senescence reshapes mitochondrial death sensitivity. This phenotype-first guide connects Bcl-2 family biology with practical cancer biology and apoptosis assay decisions.

• Dual-Action Inhibitors Drive p38α Dephosphorylation

  2026-09-18

  The reference preprint shows that selected kinase inhibitors can do more than occupy the p38α catalytic site: they can also accelerate WIP1-mediated dephosphorylation by exposing the activation-loop phospho-threonine. Structural and biochemical results establish a conformational mechanism that may guide more selective kinase-inhibitor design, while remaining a preclinical, pre-peer-review finding.

• CCCP Workflows for Mitochondrial Imaging

  2026-09-17

  CCCP converts mitochondrial proton gradient disruption into a controllable experimental variable for live-cell imaging, stress calibration, and AI-based morphology analysis. Paired with urine-derived stem cells, it can extend an emerging Alzheimer’s disease biomarker workflow without being mistaken for a clinical diagnostic test.

8370 records 1/558 page Next 12345 下5页 Last page